Andere Sprachen NeuroBo Pharmaceuticals, Inc.

Aktien

A3E2E8

US64132R4048

NRBO

Markt geschlossen - Nasdaq Andere Börsenplätze 22:30:01 03.05.2024			% 5 Tage	% 1. Jan.
3,78 ^USD	+1,34 %		+20,38 %	+2,26 %

17.04.	NeuroBo Pharmaceuticals, Inc. verabreicht den ersten Patienten in seiner klinischen Phase-1-Studie zur Bewertung von Da-1726 zur Behandlung von Fettleibigkeit	CI
01.04.	NeuroBo Pharmaceuticals, Inc. schließt die Rekrutierung von Teil 1 seiner klinischen Phase-2A-Studie zur Bewertung von DA-1241 zur Behandlung von Mash ab	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

NEUROBO TO PRESENT LATEST PRE-CLINICAL DATA ON CARDIOMETABOLIC ASSETS, DA-1241 AND DA-1726, TARGETING MASH AND OBESITY, AT SCIENTIFIC CONFERENCES IN JUNE	01.05.
Sector Update: Health Care Stocks Mixed Wednesday Afternoon	17.04.
NeuroBo Begins Dosing in Phase 1 Study of Obesity Treatment; Shares Rise	17.04.
NeuroBo Pharmaceuticals Doses First Patient in Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity	17.04.
NeuroBo Pharmaceuticals, Inc. Doses First Patient in Its Phase 1 Clinical Trial Evaluating Da-1726 for the Treatment of Obesity	17.04.
NeuroBo Pharmaceuticals Completes Enrollment of Part 1 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH	01.04.
NeuroBo Pharmaceuticals, Inc. Completes Enrollment of Part 1 of Its Phase 2A Clinical Trial Evaluating DA-1241 for the Treatment of Mash	01.04.
NeuroBo Pharmaceuticals Reports Year End 2023 Financial Results and Provides Corporate Update	28.03.
NeuroBo Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28.03.
NeuroBo Pharmaceuticals to Continue Trial of Liver Disease Treatment Candidate -- Shares Down	13.03.
NeuroBo Pharmaceuticals Receives Safety Review Committee Approval to Continue With Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH	13.03.
NeuroBo Pharmaceuticals, Inc. Receives Safety Review Committee Approval to Continue with Its Phase 2A Clinical Trial Evaluating DA-1241 for the Treatment of Mash	13.03.
NeuroBo Pharmaceuticals Names Marshall Woodworth Finance Chief	04.03.
NeuroBo Pharmaceuticals Appoints Seasoned Life Science Executive Marshall Woodworth as Chief Financial Officer	04.03.
NeuroBo Pharmaceuticals, Inc. Announces the Appointment of Marshall Woodworth as Chief Financial Officer	04.03.
NeuroBo Pharmaceuticals : Appoints Seasoned Life Science Executive Marshall Woodworth as Chief Financial Officer - Form 8-K	04.03.
NeuroBo Pharmaceuticals, Inc. Receives First Site IRB Approval for Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity	29.02.
NeuroBo Pharmaceuticals Receives First Site IRB Approval for Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity	29.02.
NeuroBo Pharmaceuticals to Participate in the BIO CEO & Investor Conference	12.02.
US Equity Markets Close Higher Thursday Following Jobless Claims Data	01.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen NeuroBo Pharmaceuticals, Inc.

Aktien

A3E2E8

US64132R4048

NRBO

Andere Sprachen

Filter